Beijing Balance Medical Technology Co., Ltd (SHA: 688198) announced that its independently developed transcatheter pulmonary valve system has been approved for market launch by China’s National Medical Products Administration (NMPA) – the company’s third interventional valve product cleared through the NMPA Special Review Procedure for Innovative Medical Devices, designed to meet the clinical needs of a broad spectrum of patients requiring transcatheter pulmonary valve replacement (TPVR).
Contents
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Action | Market approval (Class III implantable device) |
| Product | Transcatheter pulmonary valve system for TPVR |
| Review Pathway | Special Review Procedure for Innovative Medical Devices – Balance Medical’s third valve product approved via this route |
| Announcement Date | 13 Oct 2026 |
| Developer | Beijing Balance Medical Technology Co., Ltd (SHA: 688198), independently developed |
| Next Steps | Commercial launch across TPVR patient populations; pricing and rollout timeline Not disclosed |
Device Profile & Design Innovation
- Biomimetic Stent Architecture: The stent is biomimetically engineered to match the anatomical shape of a healthy human right ventricular outflow tract (RVOT) – rather than adapting to diseased, deformed anatomy.
- “Remodel‑First” Implant Concept: Using preoperative imaging analysis to determine the optimal transthoracic access site, the surgeon remodels the main pulmonary artery on a beating heart via a small‑incision, direct‑vision approach to closely resemble normal anatomy before transcatheter valve deployment.
- Morphology‑Agnostic Standardization: Unlike existing TPVR devices that must conform to deformed pulmonary artery geometries, this system relies on a standardized normal pulmonary artery structure – regardless of the patient’s native morphology (typically categorized into 5 types), the vessel is remodeled to accommodate secure anchoring of the device.
Transthoracic Access – Key Advantages
| Advantage | Detail |
|---|---|
| Minimally Invasive & Direct Access | A minor incision through the conus arteriosus ensures low trauma, excellent coaxial alignment, and avoids traversing the tricuspid valve – eliminating tricuspid injury risk inherent to peripheral vascular routes while ensuring controllable delivery and deployment |
| Secure Anchoring & Zero Leakage | Pre‑shaping the main pulmonary artery prior to implantation ensures firm anchoring and zero paravalvular leak |
| Enhanced Structural Integrity | Transthoracic access bypasses the need for high stent flexibility, enabling superior radial strength and eliminating the risk of stent fracture |
| Optimized Hemodynamics | Leaf morphology and frame design achieve hemodynamic characteristics equivalent to surgical bioprosthetic valves |
Market Impact & Outlook
- Broadened TPVR Eligibility: By remodeling the pulmonary artery to a standardized anatomy, the system can treat patients across all 5 main pulmonary artery morphological types – a population that existing geometry‑dependent TPVR devices struggle to address uniformly.
- Durability Differentiation: Elimination of stent fracture risk via superior radial strength, combined with zero paravalvular leak, targets the two most consequential long‑term failure modes in transcatheter pulmonary valves – particularly important for the young, often pediatric‑onset RVOT dysfunction population facing decades of implant life.
- Third Innovative‑Device Approval: The clearance cements Balance Medical’s position as one of China’s most prolific structural heart innovators, with three NMPA Special Review approvals in interventional valves – deepening its franchise from aortic and pulmonary valve platforms.
- China Structural Heart Market: Congenital heart disease repair in China generates a large cohort of patients with RVOT dysfunction requiring pulmonary valve replacement; a domestic, morphology‑agnostic TPVR option reduces reliance on imported devices and expands treatable patient numbers.
- Hybrid Procedure Paradigm: The small‑incision, beating‑heart, direct‑vision approach blends surgical precision with transcatheter delivery – a hybrid model that may set a new procedural standard in pulmonary valve interventions.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding commercial launch, clinical adoption and market potential of Balance Medical’s transcatheter pulmonary valve system. Actual results may differ materially due to risks including hospital adoption, reimbursement coverage, long‑term durability data, and competitive dynamics in structural heart devices.-Fineline Info & Tech
